Xu et al. [24] evaluated the molecular mechanisms of anlotinib in GBM and found that it significantly restricted the proliferation, migration, and invasion of human GBM cells (A172, U87, U251) in a dose-dependent manner through the mediation of the JAK2/STAT3/VEGFA signaling pathway. This evidence concerns the gene STAT3 and glioblastoma.